CG Oncology

IPO

Focused on the Future of Bladder Cancer

Public · Irvine, United States · Founded 2010 · $317.6M raised

Headquarters
Irvine, California
Employees
51–200
Founded
2010
Business Model
B2B
Total Funding
$317.6M
Last Round
$105.0M Series FAug 2023
Rounds
6
Type
Public

About

CG Oncology (formerly Cold Genesys) is a late-stage clinical biopharmaceutical company focused on developing and commercializing bladder-sparing immunotherapies. Its lead product candidate, cretostimogene grenadenorepvec, is an investigational engineered oncolytic immunotherapy (OIT) for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). Founded in 2010, the company completed its IPO on Nasdaq in January 2024. CG Oncology's vision is a world where urologic cancer patients benefit from innovative immunotherapies that allow them to live with dignity and enhanced quality of life.

Summary

CG Oncology is a Biotech company based in Irvine, United States, founded in 2010. It has raised $317.6M in total across 6 rounds, most recently a $105.0M Series F round in Aug 2023. Investors include TCG Crossover, ORI Capital and Longitude Capital.

Tech & App Stack

5 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

IPOJan 2024
$380.0M

Sign up to see all 7 events

Funding: Series A through Series F. Amounts, valuations, and investors where available.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

CG Oncology on Indexed.vc
<a href="https://indexed.vc/companies/cg-oncology"><img src="https://indexed.vc/api/badge/company/cg-oncology" alt="CG Oncology on Indexed.vc" width="260" height="76" /></a>